Watchlist Price Alert

Innoviva Inc. (INVA)

NASDAQ: INVA · Real-Time Price · USD

21.80

0.11 (0.51%)

At close: Jun 16, 2025, 3:59 PM

22.08

1.28%

Pre-market: Jun 17, 2025, 04:01 AM EDT

0.51% (1D)

Bid	20.07
Market Cap	1.37B
Revenue (ttm)	373.3M
Net Income (ttm)	-59.72M
EPS (ttm)	-0.95
PE Ratio (ttm)	-22.95
Forward PE	8.09
Analyst	Buy

Ask	22.09
Volume	743,209
Avg. Volume (20D)	867,452
Open	21.69
Previous Close	21.69
Day's Range	21.57 - 22.02
52-Week Range	15.70 - 21.99
Beta	0.37

About INVA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol INVA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for INVA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

News

5 days ago · businesswire.com

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partn...

1 week ago · businesswire.com

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

WALTHAM, Mass. & GENEVA, Switzerland--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Deve...

2 weeks ago · businesswire.com

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...

4 weeks ago · businesswire.com

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the United States commercial availability of ZEVTERA® (ceftobipro...

3 months ago · 247wallst.com

Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks

If you work in the biotech industry, you might know the name Alex Denner.